Stamos Capital gave its Amgen investment a hearty boost, snatching up 2,760 more shares in Q4—a 69.5% increase. Stamos Capital Partners L.P.'s holdings in Amgen were worth $1,754,000 as of its most ...

In the latest trading session, Amgen (AMGN) closed at $277.29, marking a -1.89% move from the previous day. This change lagged the S&P 500's 0.13% gain on the day. At the same time, the Dow lost 1.33% ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

Advisors Capital Management upped its Amgen stake by 6.2% in Q4, scooping up an extra 3,427 shares valued at $15.3 million. Amgen’s fourth-quarter earnings beat expectations with a $5.31 per share ...

DelveInsight's "ENTYVIO Market Size, Forecast, and Market Insight Report" highlights the details around ENTYVIO, a gut-selective ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition marked by the accumulation of IgG4-positive plasma ...

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...